Özet:

Backgroundː In this study, we aimed to examine the effect of Sodium Glucose Cotransporter 2 inhibitors (SGLT-2i) on routine laboratory test results at 12 weeks of follow-up among type 2 diabetes mellitus (T2D) patients using empagliflozin and dapagliflozin. Methodsː Three hundred ten patients with a diagnosis of T2D (over 18 years of age) with SGLT-2i added to stable triple combination therapy were included in this study. Patients who received either empagliflozin (25 mg once daily) (n:170) or dapagliflozin (10 mg once daily) (n:140) in addition to their current treatment regimen were divided into two groups. Laboratory findings of all patients were recorded before treatment and during follow-up in the 12 weeks. Resultsː Both empagliflozin and dapagliflozin had similar profiles of improvement of mean fasting blood glucose, and HbA1c. High improvement in lipid profiles and spot urinary parameters were detected in dapagliflozin group compared to empagliflozin group. At 12-week follow-up, change in other laboratory parameters did not differ significantly between the groups. In terms of total side effects, no difference was observed between treatment groups. Conclusionsː Empagliflozin and dapagliflozin had similar effects on fasting blood glucose and HbA1C at 12-week follow-up, while greater improvement in lipid profiles and urinary parameters was detected in those treated with Dapagliflozin.

Anahtar Kelimeler: